GlaxoSmithKline (GSK)
Ticker: NYSE: GSK, LSE: GSK
Headquarters: London, United Kingdom
Founded: 2000 (merger of Glaxo Wellcome and SmithKline Beecham)
CEO: Emma Walmsley
Market Cap: ~£70B (2026)
Overview
GlaxoSmithKline (GSK) is a global healthcare company headquartered in London, UK, with significant investments in neuroscience research. The company was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000, creating one of the world's largest pharmaceutical companies. GSK operates in three main divisions: Vaccines, Specialty Medicines, and General Medicines[@gsk2025].
Under CEO Emma Walmsley, GSK has restructured its R&D approach, focusing on science-led differentiation in vaccines, immunology, and infectious diseases, while maintaining selective investments in neuroscience. The company has deliberately reduced its exposure to traditional CNS (central nervous system) drugs in favor of higher-margin specialty areas, though it maintains an active neuroscience pipeline with several programs in clinical development.
Financial Overview
| Metric | Value |
|--------|-------|
| Market Cap | ~£70B (2026) |
| 2025 Revenue | ~£30B |
| R&D Budget | ~£5B annually |
| Employees | ~70,000 |
Key Financial Events
- 2000: Merger of Glaxo Wellcome and SmithKline Beecham
- 2014: Divested oncology portfolio to Novartis
- 2019: Acquired Tesaro (cancer immunotherapy)
- 2021: Consumer Health joint venture with Pfizer (now Haleon spin-off)
- 2022: Acquisition of Sierra Oncology ($1.9B)
...GlaxoSmithKline (GSK)
Ticker: NYSE: GSK, LSE: GSK
Headquarters: London, United Kingdom
Founded: 2000 (merger of Glaxo Wellcome and SmithKline Beecham)
CEO: Emma Walmsley
Market Cap: ~£70B (2026)
Overview
GlaxoSmithKline (GSK) is a global healthcare company headquartered in London, UK, with significant investments in neuroscience research. The company was formed through the merger of Glaxo Wellcome and SmithKline Beecham in 2000, creating one of the world's largest pharmaceutical companies. GSK operates in three main divisions: Vaccines, Specialty Medicines, and General Medicines[@gsk2025].
Under CEO Emma Walmsley, GSK has restructured its R&D approach, focusing on science-led differentiation in vaccines, immunology, and infectious diseases, while maintaining selective investments in neuroscience. The company has deliberately reduced its exposure to traditional CNS (central nervous system) drugs in favor of higher-margin specialty areas, though it maintains an active neuroscience pipeline with several programs in clinical development.
Financial Overview
| Metric | Value |
|--------|-------|
| Market Cap | ~£70B (2026) |
| 2025 Revenue | ~£30B |
| R&D Budget | ~£5B annually |
| Employees | ~70,000 |
Key Financial Events
- 2000: Merger of Glaxo Wellcome and SmithKline Beecham
- 2014: Divested oncology portfolio to Novartis
- 2019: Acquired Tesaro (cancer immunotherapy)
- 2021: Consumer Health joint venture with Pfizer (now Haleon spin-off)
- 2022: Acquisition of Sierra Oncology ($1.9B)
Neuroscience Pipeline
GSK has an active neuroscience division focused on multiple neurological and psychiatric conditions. While not as large as competitors like Biogen or Eli Lilly, GSK maintains strategic programs in high-need neurodegenerative and psychiatric indications[@gsk2026].
Alzheimer's Disease Programs
| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| GSK-231 | [Alzheimer's disease](/diseases/alzheimers-disease) | [Tau aggregation inhibitor](/mechanisms/tau-aggregation) | Phase 1 |
| GSK-452 | [Alzheimer's disease](/diseases/alzheimers-disease) | [Amyloid-beta antibody](/mechanisms/amyloid-beta) | Phase 1 |
GSK's approach to Alzheimer's focuses on tau-targeted therapies, reflecting the company's view that amyloid-targeting approaches have shown limited efficacy. The tau aggregation inhibitor program represents a strategic bet on alternative mechanisms.
Parkinson's Disease Programs
| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| GSK-123 | [Parkinson's disease](/diseases/parkinsons-disease) | [LRRK2 inhibitor](/genes/lrrk2) | Phase 1 |
The LRRK2 inhibitor program addresses the most common genetic cause of Parkinson's disease. GSK-123 targets the leucine-rich repeat kinase 2 protein, which is implicated in approximately 5-10% of familial Parkinson's cases.
Historical: SIRT1 Activator Programs (Sirtris)
GSK acquired Sirtris Pharmaceuticals in 2008 to develop SIRT1 activators for metabolic and aging-related diseases. Although the programs have shifted focus, the SIRT1 activator platform remains historically significant:
| Drug | Indication | Mechanism | Stage | Status |
|------|------------|-----------|-------|--------|
| SRT2104 | Alzheimer's disease | SIRT1 activator | Phase 2 | Completed |
| SRT3025 | Neurodegeneration | SIRT1 activator | Phase 1 | Completed |
Key learnings from Sirtris programs:
- SRT2104 demonstrated safety but limited efficacy in Phase 2
- Bioavailability challenges led to development of next-generation compounds
- NAD+ boosting strategies now preferred over direct SIRT1 activators
- Program shifted toward mitochondrial dysfunction approaches
See [SIRT1 Activators for Parkinson's Disease](/mechanisms/sirt1-activators-parkinsons) for mechanism details.
Other CNS Programs
| Drug | Indication | Mechanism | Phase |
|------|------------|-----------|-------|
| GSK-303 | [ALS](/diseases/amyotrophic-lateral-sclerosis) | [SOD1 inhibitor](/genes/sod1) | Phase 1 |
| GSK-445 | Depression | [NMDA modulator](/mechanisms/glutamate-excitotoxicity) | Phase 2 |
| GSK-567 | Schizophrenia | M4 agonist | Phase 2 |
Research Partnerships
GSK maintains active partnerships in neuroscience research:
- 23andMe: Genetic data partnership leveraging large-scale human genetic data for drug target discovery
- University of Cambridge: Neuroscience research collaborations including early-stage programs
- University College London: Alzheimer's disease research partnerships
- Michael J. Fox Foundation: Parkinson's disease research funding
Historical CNS Products
GSK has historically been a major player in CNS drugs, though many key products have lost patent protection:
- Requip (ropinirole): [Parkinson's disease](/diseases/parkinsons-disease) treatment (now generic)
- Wellbutrin (bupropion): Depression treatment (now generic)
- Zyban (bupropion): Smoking cessation (now generic)
- Trileptal (oxcarbazepine): [Epilepsy](/diseases/epilepsy) treatment (now generic)
- [Biogen](/companies/biogen)
- [Eli Lilly](/companies/eli-lilly)
- [Roche](/companies/roche)
- [Denali Therapeutics](/companies/denali-therapeutics)
- [Tauopathies](/mechanisms/tauopathies)
- [Amyloid-beta](/mechanisms/amyloid-beta)
- [Protein Aggregation](/mechanisms/protein-aggregation)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
Strategic Outlook
GSK's neuroscience strategy focuses on:
Selective entry: Targeting specific mechanisms with strong biological rationale (tau, LRRK2)
Partnership model: Leveraging academic and biotech partnerships rather than internal-only development
Risk management: Maintaining Phase 1/2 programs while avoiding late-stage Alzheimer's betsThe company faces competition from specialized neuroscience companies like Biogen, Eli Lilly, and Roche in Alzheimer's, and from companies like Denali Therapeutics in Parkinson's.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
GlaxoSmithKline, London Stock Exchange: GSK (2026)
GSK Annual Report 2025, Company Overview (2025)
GSK Pipeline, Neuroscience Programs (2026)